Nasdaq

BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I ...

- BridgeBio will also share 15-month Phase 2 data and review the Phase 3 clinical trial design of BBP-418, a potential therapeutic for patients with LGMD2I, with initiation of its Phase 3 study ...
Targeted Oncology

Measuring the Impact of Virtual Collaborative Mental Health Care in Breast Cancer

Researchers explore the impact of virtual collaborative care on mental health and quality of life for breast cancer patients, revealing significant improvements.
Harvard Business School

Measuring Inequality beyond the Gini Coefficient May Clarify Conflicting Findings

Blesch, Kristin, Oliver P. Hauser, and Jon M. Jachimowicz. "Measuring Inequality beyond the Gini Coefficient May Clarify Conflicting Findings." Nature Human Behaviour 6, no. 11 (November 2022): ...
Seeking Alpha

The Business Impact of Promotions and Measuring Employee Motivation and Commitment: New Findings from the ADP Research Institute

New quarterly report series, Today at Work, leverages proprietary data to deliver a comprehensive view of the world of work. In the September issue of Today at Work – "The Hidden Truth About ...
Seeking Alpha

BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)

- BridgeBio has developed a validated bioassay that directly measures glycosylated ⍺DG, which is central to LGMD2I disease, and enables monitoring of responses to disease-modifying therapies in LGMD2I ...